Vestal Point Capital, LP

CIK: 0001974915Latest portfolio: $2.9B · Q4 2025

Holdings

76

Total Value

$2.9B

New Positions

24

Closed Positions

29

#StockSharesValue% PortfolioChangeType
1
ABVXAbivax SA
1,900,000$256.2M8.71%+900K
2
NDQInvesco QQQ Trust Series 1
350,000$215.0M7.31%NEWPut
3
ACLXArcellx Inc
2,925,000$190.7M6.48%+1.7M
4
TERNTerns Pharmaceuticals Inc
4,500,000$181.8M6.18%NEW
5
BMRNBioMarin Pharmaceutical Inc
3,000,000$178.3M6.06%+2.2M
6
GMEDGlobus Medical Inc
1,275,000$111.3M3.78%+25K
7
NRIXNurix Therapeutics Inc
4,690,000$89.0M3.02%+1.2M
8
ALCAlcon AG
1,105,000$87.1M2.96%+5K
9
DC4Dexcom Inc
1,275,000$84.6M2.88%+625K
10
MRKMerck & Co Inc
775,000$81.6M2.77%NEW
11
TSHATaysha Gene Therapies Inc
13,750,000$75.6M2.57%+8.3M
12
ABTAbbott Laboratories
600,000$75.2M2.56%+350K
13
IMTXImmatics NV
6,125,000$64.3M2.19%-225,000
14
TYRATyra Biosciences Inc
2,425,000$63.8M2.17%
15
BCAXBicara Therapeutics Inc
3,575,000$60.2M2.05%-1,525,000
16
ARWRArrowhead Pharmaceuticals Inc
900,000$59.8M2.03%NEW
17
ELVNEnliven Therapeutics Inc
3,830,000$59.0M2.01%+2.7M
18
IRONDisc Medicine Inc
735,000$58.4M1.98%+235K
19
JAZZJazz Pharmaceuticals PLC
290,000$49.3M1.68%-210,000
20
DAWNDay One Biopharmaceuticals Inc
5,200,000$48.5M1.65%+2.5M
21
LXEOLexeo Therapeutics Inc
4,475,000$44.4M1.51%+1.2M
22
ANROAlto Neuroscience Inc
2,485,000$44.2M1.50%+1.5M
23
APGEApogee Therapeutics Inc
550,000$41.5M1.41%+125K
24
OLMAOlema Pharmaceuticals Inc
1,650,000$41.3M1.40%NEW
25
AXSMAxsome Therapeutics Inc
210,000$38.4M1.30%+60K

Quarterly Changes

New Positions

Closed Positions

Increased Positions

NameSharesChange
SLDB5.8M+2.8M
ELVN3.8M+2.7M
DAWN5.2M+2.5M
ACLX2.9M+1.7M
LXEO4.5M+1.2M
NRIX4.7M+1.2M
ABVX1.9M+900K
ABT600K+350K
IRON735K+235K
AGIO325K+198K

Decreased Positions

NameSharesChange
GON11.3M-5905000
DYN120K-2655000
YB4P1.6M-2409000
BCAX3.6M-1525000
FATE1.7M-790000
ASND175K-425000
RVMD295K-335000
IMTX6.1M-225000
ALEC755K-225000
JAZZ290K-210000

Sector Breakdown

HealthcareNaN% ($InfinityT)
Unknown0.0% ($21500884621316411392.0T)

Filing History

QuarterFiling DatePortfolio ValueHoldings
Q4 2025Feb 17, 2026$2.9B76
Q3 2025Nov 14, 2025$2.2T81
Q2 2025Aug 14, 2025$1.9T72
Q1 2025May 15, 2025$1.4T63
Q4 2024Feb 14, 2025$1.7T73
Q3 2024Nov 14, 2024$1318.6T69
Q2 2024Aug 14, 2024$1341.1T60
Q1 2024May 14, 2024$1209.2T58
Q4 2023Feb 13, 2024$944.0T48

Fund Information

CIK0001974915
Most Recent FilingFeb 17, 2026
Number of Filings9

Vestal Point Capital, LP is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $2.9B across 76 holdings. The largest position is Abivax SA (ABVX), representing 8.7% of the portfolio. Compared to the previous quarter, the fund opened 25 new positions and closed 30 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.